Who we are

CIS region has undergoing major changes in regulatory framework related to Eurasian Economic Union (EAEU) regulations. PharmaLex is a global company with local representatives operating all over the globe region, including CIS. We have established and maintained a global network of local representatives in the CIS region since 2012.

  • Countries: Russia, Kazakhstan, Uzbekistan, Tajikistan, Kyrgistan, Mongolia, Turkmenistan, Ukraine, Belarus, Georgia, Azerbaijan, Armenia and Moldova.
  • Well-established local representatives with local expertise and connections.
  • Established access and f2F meetings with the Health Authorities, such as FGBU (Russia).
  • We cover all of the services offered by PharmaLex across the CIS region, including end-to-end services from the pre-submission regulatory strategy, to the marketing authorisation and the life cycle management activities.

For customers looking for support in the CIS region, PharmaLex offers the option to have a single point of contact, who will manage and oversee entire functions as well as manage the liaison between our customers and our local experts on site.

Local Contact

  • Laura Monkiene
    Director, Principal Consultant Regulatory Affairs

What our clients say about us

We are working with a number of large pharma companies and are looking to create a consortium of partners to collect feedback on expertise, availability and outcomes. If you would be interested in joining our consortium, please contact us on contact@pharmalex.com.

  • Thanks so much for your support over the past 30 days. Your commitment and timely communication have made working with you all a pleasant experience.

    US Biotech
    Senior QA Associate
  • Highly competent, knowledgeable, absolutely reliable and dedicated to the projects

    Europe based medium-sized biotech development company
    Senior Director
  • Provided honest feedback and collaborative working solutions to obstacles

    South Korea based medium sized company
    Manager
  • PharmaLex is dedicated to delivering a comprehensive portfolio while their modular approach allows tailor-made solutions. They acknowledge our feedback, modify their approach and adapt accordingly.

    Top 10 Pharma Company
    President